

November 4, 2008



Oculus Innovative Sciences to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11

PETALUMA, Calif.--(BUSINESS WIRE)--

Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, today announced that it will present at the Rodman & Renshaw 10th Annual Healthcare Conference, to be held on November 10-12 at The Palace Hotel in New York City.

Hoji Alimi, Oculus' founder and CEO, is scheduled to speak on Tuesday, November 11, 2008 at 11:10 a.m. ET (8:10 a.m. PT) and will discuss the company's strategic initiatives, commercial activities, product pipeline and market opportunities.

Interested parties can access a live audio webcast and slide presentation at <http://ir.oculusis.com/events.cfm>. An archived presentation will be available on the company's web site for 30 days.

About Oculus

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized primarily in the United States, Europe, India, China and Mexico for the treatment of wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recent Phase II clinical trial of Microcyn Technology conducted in the U.S. met its primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America. More information can be found at www.oculusis.com.

Source: Oculus Innovative Sciences, Inc.